Tax-exempt hospitals in the 340B drug savings program provided $51.7 billion in total benefits to their communities in 2015, the most recent year for which data is available, according to an analysis released today by the AHA. “Savings from the 340B drug savings program allow eligible hospitals to provide a multitude of benefits to communities with a significant number of vulnerable patients,” said AHA President and CEO Rick Pollack. “These benefits go well beyond financial assistance for needy patients and include care and services such as wellness clinics, nutritional services and mental health clinics, the addition of nurses, social workers and transportation services to serve vulnerable patients and many other vital services that would otherwise be unavailable.” Funded by drug company discounts, not federal dollars, the 340B program was created by Congress more than 25 years ago “to stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services.”

Headline
The Wall Street Journal today published a letter to the editor from AHA General Counsel Chad Golder responding to a May 7 editorial criticizing the 340B Drug…
Headline
The AHA today urged Eli Lilly to abandon its 340B Drug Pricing Program claims-data policy and work with the AHA to develop a functional third-party…
Headline
The AHA again is asking the Health Resources and Services Administration to take action after Eli Lilly warned hospitals that they could lose access to…
Headline
The Washington Post yesterday published a letter to the editor from AHA President and CEO Rick Pollack responding to an April 18 editorial criticizing the 340B…
Headline
The Health Resources and Services Administration should abandon its consideration of a 340B rebate model pilot program because “a rebate mechanism of any kind…
Headline
The AHA and others April 17 filed an amicus brief requesting the U.S. Court of Appeals for the 4th Circuit grant en banc review of a panel decision that…